The week in prescription drug pricing: what moved, what it means for patients, and what comes next.
P4AD patient advocates from 10 states across the country travelled to D.C. this week to meet with lawmakers on both sides of the aisle.
News Sep 5, 2025Yesterday morning, the U.S. Court of Appeals For The Third Circuit rejected Bristol Myers Squibb (BMS) and Janssen’s challenge to the Medicare Drug Price Negotiation Program.
News Aug 29, 2025It’s been four weeks since Trump sent letters to 17 pharmaceutical companies demanding they align prescription drug prices with other high income nations, and Big Pharma is working hard to avoid any…
News Aug 23, 2025AstraZeneca, Bristol Myers Squibb, Eli Lilly, and Merck have launched a new lobbying group aimed squarely at undermining the popular Medicare Drug Price Negotiation Program — the most significant…
News Aug 15, 2025Fierce Pharma’s latest ranking of the most expensive drugs in the U.S. underscores the rapid escalation in launch prices, driven primarily by gene therapies priced between $2.2 million and $4.25 million per dose.
News Aug 8, 2025This week saw three blows to pharma’s multi-million dollar legal campaign against the Medicare Negotiation Program.
News Aug 4, 2025The ORPHAN Cures Act is proving even more destructive than initially reported.
News Aug 1, 2025Despite one in three Americans being unable to afford their prescription drugs, pharma companies raised prices in July on over 150 brand-name medications as part of their mid-year price hikes.
News Jul 25, 2025The FDA is continuing to build out its new priority review voucher program, now formally adding “affordability” as one of the priority criteria when considering vouchers.
News Jul 18, 2025This week, CMS announced that 33 states, DC, and Puerto Rico will join an initiative intended to improve access and lower costs for gene therapies for sickle cell disease (SCD), a condition that…
